Jack Allen
Stock Analyst at Baird
(0.83)
# 3,787
Out of 4,876 analysts
41
Total ratings
34.38%
Success rate
-15.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.10 | +263.64% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.20 | +650.00% | 3 | May 14, 2025 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.41 | +146.06% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $7.45 | +436.91% | 2 | Nov 15, 2024 | |
| VOR Vor Biopharma | Maintains: Outperform | $22 → $14 | $0.89 | +1,473.03% | 3 | Nov 8, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $64.77 | +63.66% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $9.61 | +87.30% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $22.17 | +711.91% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $2.80 | +185.71% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $46.70 | +11.35% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $32.02 | +162.34% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $2.41 | +231.95% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.96 | +418.51% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.49 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $2.97 | +203.03% | 1 | Oct 7, 2021 |
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.10
Upside: +263.64%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.20
Upside: +650.00%
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.41
Upside: +146.06%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $7.45
Upside: +436.91%
Vor Biopharma
Nov 8, 2024
Maintains: Outperform
Price Target: $22 → $14
Current: $0.89
Upside: +1,473.03%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $64.77
Upside: +63.66%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $9.61
Upside: +87.30%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $22.17
Upside: +711.91%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $2.80
Upside: +185.71%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $46.70
Upside: +11.35%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $32.02
Upside: +162.34%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $2.41
Upside: +231.95%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.96
Upside: +418.51%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.49
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $2.97
Upside: +203.03%